Introduction
Environmental factors, such as cigarette smoking, have long been suspected to contribute to human breast cancer. Epidemiological studies have reported conflicting associations between cigarette smoking and breast cancer risk. Although some studies have failed to show increased breast cancer in women who smoke (Lash and Aschengrau, 2002; Fink and Lash, 2003) , other studies indicate a role of cigarette smoke in the etiology of breast cancer (Bennett et al., 1999; Wells, 2000) . Some recent studies have reported that smoking increases breast cancer, particularly in those females who start smoking at younger ages (Reynolds et al., 2004; Johnson, 2005; Nagata et al., 2006) .
Biological studies support the hypothesis that cigarette smoking plays a role in breast carcinogenesis. Chemical and animal bioassay studies indicate that tobacco smoke contains approximately 4800 compounds and approximately 100 of these are carcinogens, cocarcinogens or mutagens (Hoffmann et al., 2001; Hecht, 2002) . Tobacco smoke compounds such as benzo(a)pyrene (el-Bayoumy et al., 1995) and 7, 12-dimethylbenzanthracene (Kumar et al., 1990) are proven mammary carcinogens. Evidence suggests that smokers metabolize cigarette constituents in their breast tissue; nicotine and its metabolite, cotinine, have been found in the breast secretions of nonlactating, women smokers (Petrakis et al., 1978) and DNA adducts have also been reported in the breast tissue of smokers (Perera et al., 1995) . Cigarette smoke condensate (CSC) has been used as a surrogate to study the genotoxic and other effects of cigarette smoke in many model systems (DeMarini, 2004) . We have shown earlier that the spontaneously immortalized human breast epithelial cell line, MCF10A, is transformed by CSC in culture (Narayan et al., 2004) . MCF10A cells spontaneously arose from culturing MCF10M cells, which were derived from a 36-year-old parous premenopausal woman with extensive fibrocystic disease, but no family history or histological evidence of breast malignancy. MCF10A cells are estrogen receptor-negative and have characteristics of normal cells including growth factor dependency, anchorage-dependent growth and lack of tumorigenecity in nude mice. Therefore, these cells are considered a model for normal breast epithelial cells and provide the opportunity to study the mechanism of transformation and tumorigenesis Tait et al., 1990) . After a single CSC treatment, MCF10A cells displayed transformed characteristics such as increased proliferation and anchorage-independent growth, and also showed increased expression of bcl-xl mRNA and protein levels (Narayan et al., 2004) .
Bcl-xL is an anti-apoptotic member of the Bcl-2 protein family, most closely related to the founding member anti-apoptotic Bcl-2 (Boise et al., 1993; Grillot et al., 1997) . bcl-xl is upregulated in breast cancer cell lines and primary breast tumors, and is considered as a marker for increased tumor grade and nodal metastasis (Schott et al., 1995; Olopade et al., 1997) . The evasion of apoptosis is considered one of the six hallmarks of cancer (Hanahan and Weinberg, 2000) . Cells expressing Bcl-xL are more likely to survive following DNA damage and can potentially accumulate new somatic mutations at higher frequencies (Cherbonnel-Lasserre et al., 1996) . The resulting persistent accumulation of damage and mutations could lead to cell-cycle deregulation, transformation and eventually carcinogenesis. We hypothesized that CSC treatment caused increased expression of Bcl-xL leading to transformation of MCF10A cells. In the present study, we determined the mechanism by which CSC causes transcriptional upregulation of bcl-xl gene expression in MCF10A cells. Our results suggest, for the first time to our knowledge, that CCAAT/enhancer-binding protein (C/EBPb) binds the bcl-xl promoter and induces its activity in MCF10A cells in response CSC treatment.
Results
CSC treatment induces bcl-xl mRNA and protein levels in MCF10A cells To determine the effect of CSC treatment on bcl-xl gene levels, we treated MCF10A cells with increasing amounts of CSC for 24 h, and bcl-xl mRNA levels were measured by reverse transcription-polymerase chain reaction (RT-PCR) (Figure 1a ). In these cells after normalization with glyceraldehyde 3-phosphate dehydrogenase mRNA, the bcl-xl mRNA expression slightly decreases at lower concentrations (2.5 mg/ml) and increases at higher concentrations of CSC treatment as compared with untreated cells. To confirm the subsequent induction of Bcl-xL protein levels, cells were treated with 25 mg/ml of CSC for different time intervals and with increasing concentrations of CSC for 24 h. Western analysis was used to determine the protein levels. The results showed an increased level of Bcl-xL protein in both time- (Figure 1b , upper panel) and concentration-dependent manners (Figure 1b , lower panel). These results indicate that CSC treatment induces bcl-xl mRNA and protein levels in MCF10A cells. The concentration of CSC used in these experiments was in the range of 0-50 mg/ml. This concentration of CSC is not as high as compared with the exposure with 10 mg of tar (CSC) present in each cigarette, which contains about 6.4 ng of benz(a)pyrene, a well-known mammary carcinogen (Stabbert et al., 2003) . In human body, components of cigarette smoke can be transported to distal organs by blood including breast. Although a critical level of carcinogens is required to trigger the process of DNA damage and carcinogenesis, it can be an accumulative effect of cigarette smoke carcinogens, instead of a single event leading to carcinogenesis in human body.
CSC induces bcl-xl promoter activity in MCF10A cells To determine how bcl-xl was induced by CSC, the human bcl-xl promoter Sevilla et al., 1999) was cloned into a pGL3-Basic Luciferase Vector (Promega Corp., Madison, WI, USA) as described in Materials and methods and was named pBcl-xLP. Transcription initiation sites were located at þ 1 and þ 78, and putative cis-regulatory elements on the pBclxLP were identified (Figure 2 ; Grillot et al., 1997; Sevilla Figure 1 Bcl-xl mRNA and protein levels are induced in MCF10A cells treated with CSC. (a) mRNA levels. Total RNA was isolated from cells treated with increasing concentrations of CSC for 24 h. RT-PCR was performed with primers specific to the bcl-xl cDNA sequence. GAPDH primers were used on the same samples as a loading control. (b) Protein levels. For the time course studies, cells were treated with 25 mg/ml of CSC for various time points (upper panel c). For the concentration curve, cells were treated with increacing amounts of CSC for 24 h (lower panel c). b-actin levels were used as a loading control. GAPDH, glycercaldehyde 3-phosphate dehydrogenase; RT-PCR, reverse transcription-polymerase chain reaction; CSC, cigarette smoke condensate. et al., 1999). The pBcl-xLP promoter had consensus sites for several transcription factors that were reported in earlier studies, such as NF-kB, Oct1, Sp proteins, GATA, STAT and others. To determine whether the pBcl-xLP was responsive to CSC treatment, promoter constructs were transfected into MCF10A cells and then the cells were treated with 25 mg/ml CSC for the time course (0-48 h) or treated with varying concentrations (0-50 mg/ml) of CSC for 24 h. Promoter activity was measured with luciferase assays. The promoter construct pBcl-xLP(À145, þ 707) was not induced by CSC treatment (data not shown); however, the promoter construct pBcl-xLP(À54, þ 647) was found to have basal promoter activity. We considered this as a wildtype promoter and will be referred to as pBcl-xLP from here onward. CSC treatment of the cells induced pBclxLP promoter activity in a time-dependent manner, with the highest time point of induction at 24 h ( Figure 3a ) and in a concentration-dependent manner, with the highest induction at 50 mg/ml of CSC treatment ( Figure 3b ). On the basis of these experiments, the optimum conditions were determined to be 25 mg/ml concentration of CSC and 24 h of treatment time. These studies suggest that pBcl-xLP promoter activity was induced in MCF10A cells by CSC treatment in a timeand concentration-dependent manner.
RT-PCR

Bcl-xL
GAPDH
Concentration curve
C/EBP-binding sites on the pBcl-xLP are responsive to CSC treatment Putative cis-elements on the bcl-xl promoter represent possible binding sites for transcription factors that can activate or repress the transcription of this gene. To determine which transcription factor was responsive for increasing pBcl-xLP expression in treated cells, sequential deletion constructs ( Figure 4a ) were transfected into MCF10A cells and treated with 25 mg/ml of CSC for 24 h, and promoter activity was measured. The results indicated that pBcl-xLP(À54, þ 647) activity was significantly induced by CSC (Figure 4b ). Basal promoter activity was reduced with pBcl-xLP(À28, þ 707), which reflected the loss of the C/EBP-binding site-I, but the CSC response was maintained, suggesting that C/EBP-binding site-I was important for the basal bcl-xl promoter activity and that it may or may not have been responsive to CSC treatment. The bcl-xl promoter activity continued to decrease as other elements were deleted. However, the CSC response was maintained up to pBcl-xLP(À28, þ 222). The promoter activity decreased at the next construct, pBcl-xLP(À28, þ 132), which represented the loss of the C/EBP-binding site-II. The loss of this site resulted in an unrecoverable decrease in promoter activity.
To further examine whether C/EBP-binding site-I and II were necessary for CSC-induced promoter activity, we mutated these sites of the pBcl-xLP promoter by sitedirected mutagenesis. The mutant constructs were then transfected into MCF10A cells that were subsequently treated with CSC. Although the wild-type promoter showed a significant induction of activity in response to CSC treatment, neither mutant promoter constructs showed a significant change in response to treatment (Figure 5a ). These results indicate that C/EBP-binding site-I and II might be CSC-responsive element on the pBcl-xLP in MCF10A cells.
C/EBPb binds to the pBcl-xLP in MCF10A cells in vitro and in vivo Two putative C/EBP sites on the pBcl-xLP were identified as being inducible by CSC. C/EBPb is one of the six C/EBP proteins and evidence suggests that it has role in human breast carcinogenesis; however, this role is not completely understood (Zahnow, 2002; Milde-Langosch et al., 2003) . Its putative role in human breast carcinogenesis made C/EBPb an appropriate target protein responsible for the upregulation in bcl-xl in CSC-treated MCF10A cells. Western analysis was used to confirm that C/EBPb was induced by CSC treatment. Two C/EBPb isoforms, LAP1 (45 kDa) and LAP2 (42 kDa), were detected in whole-cell extracts from CSC-treated MCF10A cells; however, LIP (20 kDa) was poorly expressing and could not be detected in these cells (Figures 5b and c) . Only LAP2 levels were significantly increased in a time-and concentration-dependent manner (Figures 5b and c, respectively) . These experiments suggested that C/EBPb protein levels are induced by CSC treatment.
Then we used electrophoretic mobility shift assay (EMSA) to characterize the C/EBP-binding proteins binding to the pBcl-xLP promoter in response to CSC treatment. For these experiments, 32 P-labeled double- stranded probes, identical to C/EBP-binding site-I and site-II sequences were incubated with MCF10A nuclear extract. Two DNA-protein complexes (shifted bands-I and -II) were visualized with autoradiography ( Figure 6a ). These bands represented nuclear proteins binding to the C/EBP regulatory elements on the bcl-xl promoter. To further determine the binding specificity of nuclear proteins with C/EBP-binding site-I and II oligonucleotides, the competition experiments were performed with molar excess of appropriate unlabeled wild-type or mutant oligonucleotides ( Figure 6a ). For C/EBP-binding site-I and II, the unlabeled wild-type oligonucleotide competed out the 32 P-labeled probe, in a concentration-dependent manner, as expected. However, the unlabeled C/EBP site-I mutant oligonucleotide also competed out the 32 P-labeled probe. This indicated one of the two scenarios (1) the mutant is not sufficient enough to decrease binding or (2) the binding at this site is nonspecific. Further specificity was tested by adding increasing concentrations of a nonspecific, unlabeled GAGA probe to the reactions as indicated. The unlabeled probe also competed with the 32 P-labeled wild-type probe for C/EBP-binding site-I, confirming that binding to C/EBP site-I was nonspecific. Conversely, the binding at C/EBP-binding site-II was not competed out by either the unlabeled mutant or the unlabeled nonspecific GAGA oligonucleotide, suggesting that MCF10A nuclear extract contained a protein that specially bound to C/EBP-binding site-II.
The protein binding to C/EBP-binding site-II was further confirmed with super-shift analysis. The three C/EBP proteins (C/EBPa, b and d) are expressed in mammary tissue (Sabatakos et al., 1998; Gigliotti et al., 2003) . To determine whether the binding was specific to either protein, antibodies specific to each were added to the reaction mixtures. No super-shifted bands are observed in reactions with the 32 P-C/EBP-binding site-I. The effects of CSC treatment on super-shift analysis were also analysed at C/EBP site-II. Reactions containing nuclear extract from either control or CSC-treated MCF10A cells were assembled. With control nuclear extract, addition of anti-C/EBPb antibody resulted in a super-shift similar to the one in Figure 6b ments confirmed that C/EBPb specifically binds only to the C/EBP-binding site-II on the pBcl-xLP and its binding is increased by CSC treatment, indicating that the C/EBP site-II is the target of CSC-mediated upregulation of bcl-xl gene expression.
To confirm that C/EBPb binds the bcl-xl promoter in vivo, MCF10A cells were treated with increasing concentrations of CSC for 24 h and chromatin immunoprecipitation (ChIP) analysis was performed as described in Materials and methods. PCR of the resulting DNA was performed with primers specific to the pBcl-xLP C/EBP-binding site-II. The control cells had an initial binding of C/EBPb to the bcl-xl promoter. This binding slightly decreased at 10 mg/ml of CSC and then increased at 25 and 50 mg/ml concentrations of CSC treatment (Figure 7a) . These results showed a similar pattern to that observed in the RT-PCR of bcl-xl in Figure 1a , indicating that bcl-xl mRNA levels corresponded with C/EBPb binding to and regulating the bcl-xl promoter activity in CSC-treated MC10A cells.
C/EBPb overexpression mimics pBcl-xLP promoter activity and protein expression of CSC treatment in MCF10A cells To demonstrate that CSC treatment increases C/EBPb levels, which in turn, binds and regulates bcl-xl promoter activity, we recapitulated this condition by overexpressing C/EBPb proteins and measuring pBcl-xL promoter activity in MCF10A cells. Each C/EBPb construct induced promoter activity; however, only hLAP2 had a significant induction when compared with the empty pCDNA3.1 vector (Figure 7b) . To determine the effect on Bcl-xL protein levels, each construct was separately transfected into MC10A cells. After the overexpression, cells were processed for western analysis of C/EBPb isoforms and Bcl-xL protein levels. A very efficient overexpression of C/EBPb isoforms, hLAP1, hLAP2 and hLIP, were observed in MCF10A cells (Figure 7c ). The Bcl-xL protein levels were similar in control cells and cells transfected with the empty pCDNA3.1 vector. The overexpression of hLAP1 slightly increased Bcl-xL protein levels, whereas LAP2 showed the most significant increase of Bcl-xL. Conversely, hLIP expression caused a decrease in Bcl-xL protein (Figure 7c ). LIP acts as a transcriptional dominant-negative factor of hLAP1 and hLAP2 isoforms (Descombes and Schibler, 1991) . In our experiments, results showed its dominant-negative effect as the overexpression of hLIP decreases the expression of hLAP1 and hLAP2 in MCF10A cells (Figure 7c ; Bundy et al., 2005) .
Next, we determined whether the C/EBP-binding site-I and/or II are responsive to the overexpression of C/EBPb isoforms. We cotransfected C/EBP-binding site-I or II mutant pBcl-xL plasmid with one of the C/ EBPb isoforms-overexpressing plasmids. The results showed that the overexpression of C/EBPb isoforms with pBcl-xLP mutants disrupted the promoter activity (Figures 8a and b) . Although mutations in both C/EBPbinding site-I and II abolished the hLAP2-mediated pBcl-xLP promoter activity, the effect was more prominent at mutations on C/EBP-binding site-II, which is consistent with gel shift, ChIP analysis and overexpression results. The decreased activity of C/EBPbinding site-I mutant pBcl-xLP promoter by hLIP overexpression could be because of its dominantnegative effect with hLAP2 on C/EBP-binding site-II (Figure 8a ). The effect of hLIP overexpression becomes less prominent when used with C/EBP-binding site-II mutant pBcl-xLP promoter (Figure 8b) . Thus, the presence of C/EBP-binding site-II was important for the CSC-induced and C/EBPb-induced upregulation of bclxl promoter activity in MCF10A cells. Taken together, these data indicated that C/EBPb, especially LAP2 was necessary for the upregulation of bcl-xl and mimics CSC treatment in MCF10A cells.
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Discussion
In an earlier study, CSC-induced transformation of MCF10A cells has been described (Narayan et al., 2004) . In this study, the MCF10A cell line was utilized to determine the mechanism by which cigarette smoke exposure might be linked to transformation and breast carcinogenesis. Among several aspects that might play a role in CSC-induced transformation of normal breast epithelial cells, such as compromised DNA repair (Kundu et al., 2007) , increased expression of neuropilin-1 (Narayan et al., 2004) and decreased expression of S100A2 (Feng et al., 2001) , we focused on the mechanism of transcriptional regulation of anti-apoptotic gene, bcl-xl. The bcl-xl mRNA and protein levels were increased in MCF10A cells after CSC treatment, which was consistent with our earlier findings (Narayan et al., 2004) . The increase in bcl-xl mRNA occurred through a biphasic mechanism. The base-line levels of bcl-xl in untreated cells ensured the survival of the cells in culture. CSC causes DNA damage in MCF10A cells (Kundu et al., 2007) and they respond by triggering DNA repair pathways (Narayan et al., 2004) . DNA damage overloads the repair mechanisms and most cells underwent apoptosis, resulting in the decrease in bcl-xl mRNA levels after the first treatment. The surviving cells were responsible for the remaining low levels of bclxl expression after the initial treatment. Cells expressing higher levels of bcl-xl were not removed by apoptosis and subsequent treatments produced more DNA damage, persistent mutations and the interruption of important cell regulatory mechanisms. As a result, bcl-xl expression continued to increase in a concentrationdependent manner.
Then, we determined whether the increased bcl-xl mRNA level by CSC treatment was at the transcriptional level. To determine CSC-induced transcriptional mechanism, we used a luciferase-reporter assay system for these studies. Human bcl-xl gene's promoter cloned into the luciferase-reporter gene (pBcl-xLP) was responsive to CSC treatment when transfected into MCF10A cells. Promoter deletion studies suggested that two C/ EBP cis-elements were responsible for the most significant CSC-induced increase in promoter activity. Sitedirected mutagenesis confirmed that CSC-induced pBclxLP activity was attenuated in the absence of both C/ EBP-binding sites, and the protein levels of C/EBPb were induced by CSC treatment. However, EMSA confirmed that C/EBPb bound only to the bcl-xl promoter at C/EBP-binding site-II and CSC treatment increased C/EBPb binding only to C/EBP-binding site-II in vitro and in vivo. This result is not surprising because C/EBP-binding site-I has parts of the consensus sequence, whereas C/EBP-binding site-II contains 100% of the core C/EBP consensus sequence. Overexpression studies also confirmed that the ectopic expression of C/EBPb induced pBcl-xLP promoter and Bcl-xL protein levels. Site-directed mutagenesis showed that C/EBP-binding sites on the pBcl-xLP were necessary for C/EBPb to properly regulate pBcl-xLP activity. Figure 7 (a) Shows a ChIP analysis indicating that C/EBPb is present on the bcl-xl promoter of MCF10A cells in vivo. ChIP was performed on MCF10A cells treated with increasing concentrations of CSC for 24 h. An anti-C/EBPb antibody was used to immunoprecipitate the DNA-protein complexes. PCR was performed on the isolated DNA with primers specific for C/EBP site-II on the pBcl-xLP promoter. (b and c) show that the effect of overexpression of C/EBPb on the pBcl-xLP promoter activity and Bcl-xL protein levels in MCF10A cells. Human C/EBPb overexpression constructs, LAP1, LAP2 and LIP were cotransfected with the pBcl-xLP promoter into MCF10A cells. The promoter activity was determined with luciferase activity and results were expressed as mean ± s.e. of triplicate experiments, which are representative of three different experiments (b). Western analysis of C/EBPb was used to confirm the overexpression of the appropriate construct and changes in Bcl-xL expression were assessed (c). b-actin levels were used as a loading control. *Significantly different as compared with pCDNA3.1 vector control. ChIP, chromatin immunoprecipitation. CSC, cigarette smoke condensate; C/EBP, CCAAT/enhancer-binding protein.
ChIP analysis
C/EBPb expression is a critical component in the control of mammary epithelial cell proliferation and differentiation in the functional mammary gland (Robinson et al., 1998; Seagroves et al., 1998) . C/EBPb is increased in human breast cancer (Eaton et al., 2001; Milde-Langosch et al., 2003) ; however, the mechanism(s) by which it influences breast carcinogenesis is not well established. In the present study, only C/EBPb-LAP2 protein levels were induced in time-and concentration-dependent manner following CSC treatment. Additionally, only LAP2 significantly induced pBcl-xLP activity and Bcl-xL protein levels. Although C/EBPb-LAP2 has not been fully implicated in human breast carcinogenesis, studies support its role in the disease. LAP2 is the most prevalent form of C/EBPb in human breast cancer cells (Eaton et al., 2001 ) and the overexpression of C/EBPb-LAP2 has been implicated in the transformation of human breast epithelial cells. MCF10A cells infected with a LAP2-expressing virus became anchorage independent, expressed markers of epithelial-mesenchymal transition, acquired invasive phenotypes (Bundy and Sealy, 2003) , gained epidermal growth factor-independent growth and had disruption of normal acinar structure when grown on basement membrane (Bundy et al., 2005) . These studies suggest that aberrant expression of C/EBPb isoforms, especially LAP2, contributes to breast carcinogenesis.
The following model is proposed as a starting point to uncovering the role of C/EBPb in the upregulation of bcl-xl in MCF10A cells treated with CSC (Figure 8c ). When human breast epithelial cells are exposed to CSC, cells are damaged and most of the cells undergo cellcycle arrest and/or apoptosis (Narayan et al., 2004) . In the few surviving cells, C/EBPb protein is activated by an unknown mechanism, triggering the dimerization of two C/EBPb-LAP2 monomers. These homodimers bind to C/EBP site-II on the bcl-xl promoter and transcriptionally activate the mRNA and subsequent protein expression levels of Bcl-xL. Increased levels of Bcl-xL impede the apoptotic pathway, allowing for the accumulation of DNA damage (Mendez et al., 2001 (Mendez et al., , 2005 . When genes involved in DNA repair or the apoptotic pathway are also altered, the accumulation of DNA damage can lead to cell-cycle deregulation. Disruption of apoptotic pathways may also allow for damaged cells to survive and acquire the characteristics of transformed cells. Cells overexpressing Bcl-xL can adapt to new microenvironments (Rubio et al., 2001; Fernandez et al., 2002; Espana et al., 2004; Mendez et al., 2006) , have increased potential to metastasize (Rubio et al., 2001; Fernandez et al., 2002) and are also more prone to be resistant to chemotherapy and radiation therapy (Datta et al., 1995 The results of this study indicate that C/EBPb, especially LAP2, is at least one of the transcription factors that regulate the induction of bcl-xl mRNA and protein levels in MCF10A cells treated with CSC. This and other studies place C/EBPb as a potential oncogene in breast cancer. The current study not only provides insight into the mechanism of cigarette smoke-induced breast epithelial cell transformation and carcinogenesis, but also adds to the literature that supports the link between cigarette smoking and increased breast cancer risk.
Materials and methods
Preparation of CSC CSC was prepared from the University of Kentucky Reference Cigarette 1R4F (Davis et al., 1984; Sullivan, 1984) as described earlier (Hsu et al., 1991) .
Culturing of MCF10A cells MCF10A cells were cultured and maintained in DMEM/F12 (50:50 v/v) Mixture with L-glutamine and 15 mM Hepes (Mediatech, Manassas, VA, USA). Medium was supplemented with 5% horse serum, 100 U/ml penicillin-streptomycin, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 mg/ml insulin and 10 ng/ml epidermal growth factor. The cells were grown in a humidified atmosphere of 5% CO 2 at 37 1C.
RT-PCR
RNA was isolated with TRIzol reagent (Invitrogen Corp., Carlsbad, CA, USA). For RT-PCR, a total of 0.5 mg RNA was used to make cDNA as per manufacturer's instructions (Invitrogen Corp.). In total, 2 mg of synthesized cDNA was used for PCR amplification with primers specific for bcl-xl Western blot analysis MCF10A cells were plated on 150 mm plates and allowed to grow to 50-60% confluency, then treated with CSC as described in the figure legends. After the treatment, cells were harvested and processed for the preparation of whole-cell extract. The protein levels were determined by western blot analysis (Narayan and Jaiswal, 1997) . The antibodies anti-Bcl-xL, anti-C/EBPb and anti-b-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cloning of the human bcl-xl promoter (pBcl-xLP) The human bcl-xl promoter (226-915 nt; Gene Bank Accession No. D30746) was cloned into pGL3-Basic Luciferase Vector (Promega Corp.) at XhoI and HindIII cloning sites (Sevilla et al., 1999) . The promoter cis-elements were determined by TRANSFEC v4.0 Program (TESS: Transcription Element Search System, University of Pennsylvania) and two transcription initiation sites were identified.
Cloning of pBcl-xLP deletion constructs PCR was used to make nine sequential deletion pBcl-xLP constructs. The full-length pBcl-xLP(À53 þ 647) was used as template for PCR with specific primers that amplified the appropriate regions resulting in the deletion constructs. The primers used for sequential deletion constructs were pBclxLP(À28, þ 707) sense: 5 0 -CCGCTCGAGCCACCTCCGGG AGAGTACTC-3 0 , anti-sense: 5 0 -CCCAAGCTTGTCCAAA ACACCTGCTCA-3 0 ; pBcl-xLP(À28, þ 542) sense:
0 . The PCR cycles were 1 cycle of 94 1C for 3min; 32 cycles of 941C for 1min, 551C for 1min and 72 1C for 3min; 1 cycle of 721C for 10 min. The PCR products were gel extracted with the QIAXEXII Gel Extraction Kit (Qiagen Inc., Valencia, CA, USA) and subcloned into the pGL3-Basic Luciferase Vector (Promega Corp.) at XhoI and HindIII cloning sites.
Promoter activity assays
Wild-type, mutant or deletion constructs of pBcl-xLP were cotransfected with pCMV-b-galactosidase plasmid into MCF10A cells with FuGENE-6.0 Transfection Reagent (Roche Diagnostics, Indianapolis, IN, USA). To determine the effect of CSC, cells were treated with different concentrations of CSC for indicated periods of time as shown in the respective figure legends. Cells were harvested, lysates prepared and processed for promoter activity by measuring luciferase activity. The transfection efficiency of the promoter constructs were normalized with b-galactosidase activity.
Site-directed mutagenesis
The QuikChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) was used to mutate two C/EBP sites on the pBcl-xLP construct. Primers specific for the cis-element mutations were used to perform PCR. C/EBP site-I sequence, AAAAACAAAAACCAACTAAA, was mutated to AAAA AGGGCCCAAAATAAA, using the following primers: sense, 5 0 -TGGTGCTTAAATAGAAAAAAGGGCCCAAAACTAA ATCCATACCAGCCACCT-3 0 ; anti-sense, 5 0 -GGTGGCT GGTATGGATTTAGTTTTGGGCCCTTTTTCTTTTTTCT ATCTATTTAAGCACCA-3 0 . The C/EBP site-II sequence, CCTGAGCTTCGCAATTCCTG, was mutated to CCT GAGCCACAGCATTCCTG with the following primers: sense, 5 0 -AGCAAGCGAGGGGGCTGGTTCCTGAGCCA CAGCATTCCTGTGTCGCCTTCT-3 0 ; anti-sense, 5 0 -AG AAGGCGACACAGGAATGCTGTGGCTCAGGAACCAG CCCCCTCGCTTGCT-3 0 . The PCR-amplified products were digested with DpnI to degrade the template DNA and transformed into XL-1 Blue Super-competent Cells (Strategene, La Jolla, CA, USA). Positive clones were confirmed with sequencing and amplified for isolation of the plasmid.
EMSA
Single-stranded oligonucleotides were annealed to produce double-stranded oligonucleotides for EMSA analysis. The oligonucleotides used were C/EBP-binding site-I wild-type sense: 5 0 -AAAAACAAAAACCAACTAAA-3 0 , anti-sense: 5 0 -TTTAGTTGGTTTTTGTTTTT-3 0 ; C/EBP-binding site-I mutant sense: 5 0 -AAAAGGGCCCAAAACTAAA-3 0 , anti-sense: 5 0 -TTTAGTTTGGGCCCTTTT-3 0 ; C/EBP-binding site-II wild-type sense: 5 0 -CCTGAGCTTCGCAATTCCTG-3 0 , antisense: 5 0 -CAGGAATTGCGAAGCTCAGG-3 0 ; C/EBP-binding site-II mutant sense: 5 0 -CCTAGCCACAGCATTCCTG-3 0 , anti-sense: 5 0 -CAGGAATGCTGTGGCTAGG-3 0 . The underlined nucleotides are the core of the C/EBP consensus sequence and the bold nucleotides were mutated. Doublestranded oligonucleotides were end-labeled with 32 P-g(ATP) by T4 Polynucleotide Kinase (New England BioLabs Inc., Ipswich, MA, USA). EMSA and super-shift analysis was performed with nuclear extracts (Shapiro et al., 1988) as described in earlier studies (Jaiswal et al., 2006) . The antibodies specific to C/EBPa, C/EBPb or C/EBPd proteins from Santa Cruz Biotechnology were used for super-shift analysis.
ChIP assay
ChIP analysis was carried out using a kit from Upstate Biotechnology (Lake Placid, NY, USA) as described in our earlier studies (Jaiswal et al., 2006) . The lysate was sonicated on ice for four cycles of 30 s with 20 s intervals using a Branson Sonicator 450 (Branson Power Company, Danbury, CT, USA) at a 5% duty cycle, 20% constant maximal power and with a control output of five. Anti-C/EBPb antibody (Santa Cruz Biotechnology) was used to immunoprecipitate the DNAprotein complexes, which were then eluted and heated to reverse the cross-linkages. DNA was isolated by phenolchloroform extraction and ethanol precipitation. The isolated DNA was used in PCR reactions with primers specific to C/ EBP site-II on the pBcl-xLP. The primers were C/EBP site-II sense: 5 0 -CGGGTGGCAGGAGGCCGCGGC-3 0 and antisense: 5 0 -AACTCAGCCGGCCTCGCGGTG-3 0 , resulting in a 190 bp product.
Overexpression of C/EBP MCF10A cells were plated at the density of 0.6 Â 10 6 cells per 60 mm tissue culture plate and allowed to attach overnight. The next day, 2 mg of either C/EBPb overexpression construct or empty pCDNA3.1 vector was transfected into the cells with 9 ml of FuGENE 6.0 Transfection Reagent (Roche Applied Bioscience) as described earlier. Cells were treated with CSC 24 h post transfection for an additional 24 h, and cell lysate was prepared for luciferase analysis or western analysis.
Abbreviations
C/EBP, CCAAT/enhancer-binding protein; ChIP, chromatin immunoprecipitation; CSC, cigarette smoke condensate; RT-PCR, reverse transcription-polymerase chain reaction.
